Literature DB >> 20637063

Rare incidence of methotrexate-specific lesions in liver biopsy of patients with arthritis and elevated liver enzymes.

Emilie Quintin1, Jean-Yves Scoazec, Hubert Marotte, Pierre Miossec.   

Abstract

INTRODUCTION: The present study objective was to evaluate the incidence of methotrexate (MTX)-specific liver lesions from the analysis of a liver biopsy of inflammatory arthritis patients with elevated liver enzymes.
METHODS: A case-control study was performed with 1,571 arthritis patients on long-term low-dose MTX therapy. Results of liver biopsy were analyzed in 41 patients with elevated liver enzymes. The expression of autoimmune markers was also assessed. This population was compared with 41 disease control subjects obtained from the same database, also on MTX but without elevated liver enzymes, matched for age, sex and rheumatic disease.
RESULTS: Compared with the disease controls, patients with liver biopsy showed lower disease duration and lower MTX exposure, weekly and cumulative doses, reflecting shorter treatment duration due to liver abnormalities. Liver biopsies showed 17 autoimmune hepatitis-like (AIH-like) lesions, 13 nonalcoholic steatohepatitis-like lesions, seven limited liver lesions, and two primary biliary cirrhoses. However, MTX-specific lesions with dystrophic nuclei in hepatocytes were seen in only two cases. Liver biopsy lesions were associated with autoimmune markers (P = 0.007); notably, AIH-like lesions were associated with rheumatoid arthritis and with the presence of the HLA-DR shared epitope.
CONCLUSIONS: MTX-specific liver lesions are rarely observed in arthritis patients under long-term MTX therapy and elevated liver enzymes.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20637063      PMCID: PMC2945037          DOI: 10.1186/ar3085

Source DB:  PubMed          Journal:  Arthritis Res Ther        ISSN: 1478-6354            Impact factor:   5.156


  34 in total

1.  Histologic liver abnormalities in an autopsy series of patients with rheumatoid arthritis.

Authors:  E M Ruderman; J M Crawford; A Maier; J J Liu; E M Gravallese; M E Weinblatt
Journal:  Br J Rheumatol       Date:  1997-02

2.  Etanercept treatment for three months is safe in patients with rheumatological manifestations associated with hepatitis C virus.

Authors:  H Marotte; E Fontanges; F Bailly; F Zoulim; C Trepo; P Miossec
Journal:  Rheumatology (Oxford)       Date:  2006-05-23       Impact factor: 7.580

3.  Therapy: methotrexate guidelines: compromise to reach consensus.

Authors:  Joel M Kremer
Journal:  Nat Rev Rheumatol       Date:  2009-04       Impact factor: 20.543

4.  Assessment of the European classification criteria for Sjögren's syndrome in a series of clinically defined cases: results of a prospective multicentre study. The European Study Group on Diagnostic Criteria for Sjögren's Syndrome.

Authors:  C Vitali; S Bombardieri; H M Moutsopoulos; J Coll; R Gerli; P Y Hatron; L Kater; Y T Konttinen; R Manthorpe; O Meyer; M Mosca; P Ostuni; R A Pellerito; Y Pennec; S R Porter; A Richards; B Sauvezie; M Schiødt; M Sciuto; Y Shoenfeld; F N Skopouli; J S Smolen; F Soromenho; M Tishler; M J Wattiaux
Journal:  Ann Rheum Dis       Date:  1996-02       Impact factor: 19.103

Review 5.  Risk and management of liver toxicity during methotrexate treatment in rheumatoid and psoriatic arthritis: a systematic review of the literature.

Authors:  K Visser; D M F M van der Heijde
Journal:  Clin Exp Rheumatol       Date:  2009 Nov-Dec       Impact factor: 4.473

6.  Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop.

Authors:  Robert J Fontana; Leonard B Seeff; Raúl J Andrade; Einar Björnsson; Christopher P Day; Jose Serrano; Jay H Hoofnagle
Journal:  Hepatology       Date:  2010-08       Impact factor: 17.425

7.  Rheumatological manifestations of hepatitis C: incidence in a rheumatology and non-rheumatology setting and the effect of methotrexate and interferon.

Authors:  M J Nissen; E Fontanges; Y Allam; F Zoulim; C Trépo; P Miossec
Journal:  Rheumatology (Oxford)       Date:  2005-04-26       Impact factor: 7.580

8.  Biochemical and biophysical assessment of MTX-induced liver fibrosis in psoriasis patients: Fibrotest predicts the presence and Fibroscan predicts the absence of significant liver fibrosis.

Authors:  Maartje A M Berends; Josje Snoek; Elke M G J de Jong; J Han Van Krieken; Robert J de Knegt; Martijn G H van Oijen; Peter C M van de Kerkhof; Joost P H Drenth
Journal:  Liver Int       Date:  2007-06       Impact factor: 5.828

9.  Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative.

Authors:  K Visser; W Katchamart; E Loza; J A Martinez-Lopez; C Salliot; J Trudeau; C Bombardier; L Carmona; D van der Heijde; J W J Bijlsma; D T Boumpas; H Canhao; C J Edwards; V Hamuryudan; T K Kvien; B F Leeb; E M Martín-Mola; H Mielants; U Müller-Ladner; G Murphy; M Østergaard; I A Pereira; C Ramos-Remus; G Valentini; J Zochling; M Dougados
Journal:  Ann Rheum Dis       Date:  2008-11-25       Impact factor: 19.103

Review 10.  Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research.

Authors:  C Salliot; D van der Heijde
Journal:  Ann Rheum Dis       Date:  2008-12-05       Impact factor: 19.103

View more
  16 in total

1.  Methotrexate for primary biliary cirrhosis: who is to be trusted?

Authors:  Carlo Selmi; Mauro Podda
Journal:  Dig Dis Sci       Date:  2010-11       Impact factor: 3.199

Review 2.  Clinical connection between rheumatoid arthritis and liver damage.

Authors:  Biljana Radovanović-Dinić; Snežana Tešić-Rajković; Valentina Zivkovic; Saša Grgov
Journal:  Rheumatol Int       Date:  2018-04-07       Impact factor: 2.631

3.  Significance of liver biopsy for the evaluation of methotrexate-induced liver damage in patients with rheumatoid arthritis.

Authors:  Tatsuya Osuga; Yoshihiro Ikura; Chikara Kadota; Seiichi Hirano; Yasuhiro Iwai; Takanobu Hayakumo
Journal:  Int J Clin Exp Pathol       Date:  2015-02-01

4.  IL-17 and TNF-α co-operation contributes to the proinflammatory response of hepatic stellate cells.

Authors:  A Beringer; P Miossec
Journal:  Clin Exp Immunol       Date:  2019-06-06       Impact factor: 4.330

5.  Synergistic effect of interleukin-17 and tumour necrosis factor-α on inflammatory response in hepatocytes through interleukin-6-dependent and independent pathways.

Authors:  A Beringer; N Thiam; J Molle; B Bartosch; P Miossec
Journal:  Clin Exp Immunol       Date:  2018-05-31       Impact factor: 4.330

6.  [Differential diagnosis of elevated liver transaminases in rheumatic diseases].

Authors:  W-J Mayet
Journal:  Z Rheumatol       Date:  2015-03       Impact factor: 1.372

7.  [Comorbidity of rheumatic and hepatic diseases].

Authors:  W-J Mayet; A W Lohse
Journal:  Z Rheumatol       Date:  2013-08       Impact factor: 1.372

Review 8.  Liver involvement in subjects with rheumatic disease.

Authors:  Carlo Selmi; Maria De Santis; M Eric Gershwin
Journal:  Arthritis Res Ther       Date:  2011-06-30       Impact factor: 5.156

9.  Methotrexate-associated nonalcoholic fatty liver disease with transaminitis in rheumatoid arthritis.

Authors:  Rajalingham Sakthiswary; Grace Yin Lai Chan; Ee Tzun Koh; Khai Pang Leong; Bernard Yu Hor Thong
Journal:  ScientificWorldJournal       Date:  2014-05-28

10.  Sirolimus treatment for cirrhosis or hepatocellular carcinoma patients accompanied by psoriasis after liver transplantation: A single center experience.

Authors:  Lin Zhou; Guo-Sheng Du; Li-Chao Pan; Yong-Gen Zheng; Zhi-Jia Liu; Hai-Da Shi; Shao-Zhen Yang; Xian-Jie Shi; Meng Xuan; Li-Kui Feng; Zhi-Dong Zhu
Journal:  Oncol Lett       Date:  2017-10-18       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.